<DOC>
	<DOCNO>NCT00126464</DOCNO>
	<brief_summary>RATIONALE : Estrogen cause growth breast cancer cell . Hormone therapy use fulvestrant tamoxifen may fight breast cancer block use estrogen tumor cell . Giving fulvestrant tamoxifen surgery may effective treatment breast cancer . PURPOSE : This randomized clinical trial study well give fulvestrant tamoxifen work treat postmenopausal woman undergo surgery ductal carcinoma situ breast .</brief_summary>
	<brief_title>Fulvestrant Tamoxifen Treating Postmenopausal Women Who Are Undergoing Surgery Ductal Carcinoma Situ Breast</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine , preliminarily , efficacy neoadjuvant fulvestrant , term molecular change marker estrogen pathway , cell proliferation apoptosis , epidermal growth factor pathway , postmenopausal woman newly diagnose ductal carcinoma situ breast . Secondary - Determine toxicity profile fulvestrant patient . OUTLINE : This randomize , placebo-controlled , pilot , multicenter study . Patients randomize 1 4 treatment arm . - Arm I : Patients receive oral placebo daily day 1-21 . - Arm II : Patients receive oral tamoxifen daily day 1-21 . - Arm III : Patients receive fulvestrant intramuscularly ( IM ) day 1 . - Arm IV : Patients receive fulvestrant IM arm III high dose . In arm , treatment continue absence disease progression unacceptable toxicity . All patient undergo surgical resection tumor approximately day 21 . PROJECTED ACCRUAL : A total 100 patient ( 25 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ductal carcinoma situ ( DCIS ) breast T0 disease Newly diagnose disease minimally invasive biopsy ( e.g. , vacuumassisted large core tool [ mammotome ] equivalent method ) Biopsy tissue available molecular marker analysis Baseline mammography perform within past 8 week Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age Postmenopausal Sex Female Menopausal status Postmenopausal , define 1 following : Age ≥ 60 Age ≥ 45 AND amenorrheic &gt; 1 year uterus intact Underwent bilateral oophorectomy Folliclestimulating hormone estradiol level postmenopausal range Performance status SWOG 01 Life expectancy Not specify Hematopoietic Absolute granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8.0 g/dL Hepatic SGOT and/or SGPT ≤ 2.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN Bilirubin ≤ 2.0 time ULN Renal Creatinine ≤ 2.0 mg/dL Cardiovascular No history deep vein thrombosis Pulmonary No history pulmonary embolism Other Negative pregnancy test ( clinically indicate ) No peripheral neuropathy &gt; grade 1 No underlying medical , psychiatric , social condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy More 6 month since prior hormonal therapy , include follow : Antiestrogens Estrogen Selective estrogenreceptor modulators Progestins Aromatase inhibitor Radiotherapy Not specify Surgery Not specify Other No prior therapy DCIS</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>breast cancer situ</keyword>
</DOC>